Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods.

Journal of medical virology - 1 May 2008

Carlsson Tony, Quist Anne, Weiland Ola

Abstract excerpt

Fifty consecutive patients with genotype 2 or 3 chronic hepatitis C were treated with peg-IFN alfa-2a 135 microg weekly and ribavirin (11 mg/kg body weight) daily during 24 weeks. Rapid viral response treatment week 4, end-of-treatment response, and sustained viral response were analyzed by two d...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepatitis C, Chronic
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Share to Sensitivity and Specificity

Share to Viral Load

Source

Identifiers

PMID: 18360893
DOI: 10.1002/jmv.21133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18360893-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods.PMID 18360893Read ↗

Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.Semantic proximity Read ↗

Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.Semantic proximity Read ↗

Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.Semantic proximity Read ↗

Response to combination therapy in hepatitis virus C genotype 2 and 3.Semantic proximity Read ↗

Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype.Semantic proximity Read ↗

Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.Semantic proximity Read ↗

COBAS ® AmpliPrep/COBAS ® Taqman ® HCV Quantitative Test, version 2.0: an in vitro test for hepatitis C virus RNA quantification.Semantic proximity Read ↗

Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections.Semantic proximity Read ↗

Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.Semantic proximity Read ↗

Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.Semantic proximity Read ↗

Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.Semantic proximity Read ↗

Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.